Alnylam Pharmaceuticals, Inc.
Moat Score — Alnylam Pharmaceuticals, Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Alnylam holds a foundational, extensive patent estate covering core RNAi chemistry, GalNAc conjugate delivery, and manufacturing built over more than two decades as the pioneering leader in the field, representing one of biopharma's most defensible platform-technology moats. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a specialty biopharmaceutical company, Alnylam does not compete primarily on manufacturing cost, though its established GalNAc delivery platform reduces per-program development costs versus starting an RNAi program from scratch. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Alnylam's rare-disease products address severe genetic conditions with few or no alternative treatments, supporting premium orphan-drug pricing, while its Leqvio royalty benefits from Novartis's pricing power in the large cardiovascular market. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | RNAi therapeutics do not exhibit network effects between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once rare-disease patients are stabilized on an Alnylam therapy, physicians are generally reluctant to switch without clear clinical reason, though patients could switch to emerging alternative mechanisms such as tafamidis or gene-editing approaches at treatment initiation. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The rare, severe genetic diseases Alnylam targets have small patient populations that may not economically support numerous competing therapies, providing some efficient-scale protection, though larger indications like TTR amyloidosis and cardiovascular disease attract substantial competition. |